BGLC Stock Summary and Trading Ideas (Bionexus Gene Lab | NASDAQ:BGLC)

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Bionexus Gene Lab trades on the NASDAQ stock market under the symbol BGLC.

As of February 6, 2026, BGLC stock price climbed to $2.10 with 2,380 million shares trading.

BGLC has a beta of 0.70, meaning it tends to be less sensitive to market movements. BGLC has a correlation of 0.01 to the broad based SPY ETF.

BGLC has a market cap of $3.77 million. This is considered a Sub-Micro Cap stock.

BGLC has underperformed the market in the last year with a price return of -44.9% while the SPY ETF gained +14.9%. BGLC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -61.0% and -34.8%, respectively, while the SPY returned +1.7% and -0.3%, respectively.

BGLC support price is $1.84 and resistance is $2.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BGLC shares will trade within this expected range on the day.